Breaking News, Collaborations & Alliances

I-Mab Expands Next-Gen Novel Oncology Portfolio

Expands pipeline of antibody assets leveraging cutting-edge mRNA and AI technology platforms.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

I-Mab, a clinical stage biopharmaceutical company developing novel biologics, signed two new collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company. The alliances provide I-Mab with access to transformative technologies to discover and develop oncology therapeutics. I-Mab will be developing anti-cancer antibody therapeutics through Immorna’s self-replicating mRNA platform.   Through a strategic collaboration, I-Mab will work with neo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters